Animal-Free Products for Life Science Research
The Shift towards Animal-Free Products in Life Science Research
Animal-derived products (ADPs), including antibodies, proteins, serum and other specialised reagents, have long played a significant role in biomedical and life science research. They support a wide range of applications, from cell culture and immunoassays to protein analysis and drug discovery, helping to advance our understanding of biological processes.
Nonetheless, the use and production of animal-derived reagents raise scientific concerns around batch-to-batch variability, reproducibility and ethical issues surrounding animal welfare. As a result, interest has grown in animal-free research products, including reagents produced without animal-derived components or ongoing animal use.
The current landscape of animal-free research
Animal-derived reagents remain deeply embedded in research. However, interest in animal-free alternatives is growing, driven by increasing government and regulatory support alongside demand for products with potential ethical and technical advantages.
Recent initiatives from the UK Government, European Commission and FDA have sought to accelerate the development and adoption of non-animal methods, while reducing reliance on animals in research (1-3). Notably, recent research supports this broader shift. A comprehensive analysis across seven research areas between 2003 and 2022 found that publications using non-animal methods had increased substantially over time (4).
However, non-animal methods and animal-free reagents are distinct concepts and reagent-specific evidence presents a more cautious picture. A global survey conducted in 2020–2021 found that 77% of researchers still used animal serum and 71% used animal-derived antibodies (5). Similarly, the NC3Rs recently reported that despite commercially available animal-free antibody technologies, uptake in routine research has historically remained limited (6).
Benefits of animal-free research products
Alongside ethical considerations, animal-free products can offer important research benefits. Chemically defined and recombinant products can help minimise batch-to-batch variability, while removing animal-derived components can reduce the risk of introducing unwanted biological contaminants. In some applications, human-specific alternatives may provide greater relevance to human biology.
Studies comparing animal-free and animal-derived products have shown how these benefits can translate into improved experimental performance. Examples include stronger fluorescence signals from some recombinant antibodies and comparable cell morphology, with equal or greater growth using animal-free cell culture media (7,8).
Furthermore, advances in recombinant antibody production are expanding the availability of animal-free reagents. Defined DNA sequences can be expressed using systems such as E. coli and yeast, or cell lines cultured under animal-component-free conditions, enabling recombinant antibodies to be produced without continued animal use (Figure 1).

Figure 1 – Workflow for manufacturing recombinant antibodies. Defined antibody DNA sequences are introduced into an expression system to enable controlled recombinant antibody manufacture.
Animal-free products from 2BScientific
At 2BScientific, we recognise that reducing reliance on animal-derived reagents can support both animal welfare and reliable research. We therefore support our suppliers’ animal-free initiatives and provide research tools spanning antibody research, protein biology, cell culture and immunoassay workflows.
Traditional polyclonal and hybridoma-based antibody production relies on animal immunisation, which can introduce variability between preparations. Likewise, animal isolated proteins can show lot-to-lot variation depending on their production method. Comparatively, animal-free recombinant antibodies and proteins offer a more consistent alternative through defined, controlled production systems.
Absolute Antibody uses an animal-free recombinant production platform across its catalogue reagents and custom expression services. Sequence-defined production helps reduce batch variability and supports consistent recombinant antibody and protein production. For researchers with existing antibodies, their sequencing services can also recreate existing antibodies using animal-free recombinant production.

Figure 2 - Immunofluorescence staining of Zika virus-infected A549 cells with Absolute Antibody anti-dsRNA antibody J2 (Ab01299).
LifeSpan Biosciences' dedicated range of animal-free proteins are manufactured using animal-free reagents and components, minimising the risk of trace animal-derived contamination. These proteins help minimise the risk of animal-derived contamination while providing defined, high-purity recombinant alternatives.
A major challenge in cell culture is the reliance on animal-derived supplements, whose complex composition and batch-to-batch variation can introduce experimental variability. Animal-component-free and serum-free media provide more defined culture conditions, helping improve consistency and standardisation.
FUJIFILM Biosciences offers chemically defined, animal-component-free cell culture media, including PRIME-XV T Cell CDM and PRIME-XV NK CDM, supporting T-cell and NK/NKT-cell expansion, respectively. These media provide more controlled culture conditions while reducing reliance on animal-derived materials.
Animal-derived blocking and diluent buffers can introduce batch variability and unwanted interactions with assay reagents, increasing background interference and reducing consistency. Animal-free alternatives can help minimise non-specific binding while providing more controlled assay conditions.
Kementec Solutions offers animal by-product-free blocking and diluent buffers. These BSA-free formulations are designed to improve assay reproducibility, minimise non-specific binding and reduce cross-reactivity with animal-derived antigens and antibodies.
Explore Kementec Solutions Products
Vector Laboratories offers animal-free blocking and diluent solutions for immunoassay and imaging workflows. Its R.T.U. Animal Free Blocker and Diluent contains no animal-derived proteins and helps reduce non-specific binding and background in applications including IHC, immunofluorescence, blotting and ELISpot.
Explore Vector Laboratories Products

Figure 3. Reduced non-specific background staining with Vector Laboratories’ R.T.U. Animal Free Blocker and Diluent in immunohistochemistry.
As animal-free technologies continue to develop and become more widely available, researchers have a growing range of options for reducing reliance on animal-derived materials without compromising the requirements of their experimental workflows.
Explore the animal-free research tools available through 2BScientific to identify the products best suited to your research.
Featured Supplier
Absolute Antibody specialises in recombinant antibody sequencing, engineering and expression for research, diagnostic and biopharmaceutical applications. Its recombinant production platform uses serum-free mammalian transient expression and is completely animal- and animal-component-free. Alongside a growing catalogue of recombinant antibodies and proteins, Absolute Antibody provides custom sequencing, engineering and expression services to support defined and reproducible antibody production.
References
-
1. Department for Science, Innovation and Technology, Home Office, Department for Environment, Food and Rural Affairs. Replacing animals in science: a strategy to support the development, validation and uptake of alternative methods
[Internet]. London: UK Government; 2025 Nov 11 [cited 2026 Aug 13]. Available from: https://www.gov.uk/government/publications/replacing-animals-in-science-strategy/replacing-animals-in-science-a-strategy-to-support-the-development-validation-and-uptake-of-alternative-methods.
-
2. Walder L, Pallocca G, Bastos LF, Beekhuijzen M, Busquet F, Constantino H, Corvaro M, Courtot L, Escher B, Fernandez R, Gougeon E. EU roadmap for phasing out animal testing for chemical safety assessments: recommendations from a multi-stakeholder roundtable.
Altex. 2025 Jul 16;42(3):435-50.
-
3. Gerke S, Balamut J, Wagner JK. The FDA’s plan to phase out animal testing.
Trends in biotechnology. 2026 Jan 21.
-
4. Taylor K, Modi S, Bailey J. An analysis of trends in the use of animal and non-animal methods in biomedical research and toxicology publications.
Frontiers in Lab on a Chip Technologies. 2024 Aug 19;3:1426895.
-
5. Cassotta M, Bartnicka JJ, Pistollato F, Parvatam S, Weber T, D'Alessandro V, Bastos LF, Coecke S. A worldwide survey on the use of animal‐derived materials and reagents in scientific experimentation.
Engineering in life sciences. 2022 Sep;22(9):564-83.
-
6. National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs). Accelerating the uptake of non-animal derived antibodies.
[Internet]. [cited 2026 Aug 13]. Available from: https://nc3rs.org.uk/our-portfolio/accelerating-uptake-non-animal-derived-antibodies.
-
7. Mogilever NB, Pagé MH, Solola A, Pelling AE. The creation and validation of a fully animal component-free media for select adherent cell types.
Integrative Biology. 2025;17:zyaf009.